2nd Interstitial Lung Disease Drug Development Summit
Evvnt Promotion / evvnt
Archivio
07.03.2022 - 09.03.2022 Online, USA
Time: 9:00 AM - 5:05 PM
Temi della conferenza
With SSc-ILD on the cusp of regulatory approval following closely behind Pirfenidone’s breakthrough therapy designation to treat uILD earlier this year, and investment pouring across multiple ILD phenotypes, the window of therapeutic opportunity to develop clinically defining drugs to treat interstitial lung disease is well and truly open.
With SSc-ILD on the cusp of regulatory approval following closely behind Pirfenidone’s breakthrough therapy designation to treat uILD earlier this year, and investment pouring across multiple ILD phenotypes, the window of therapeutic opportunity to develop clinically defining drugs to treat interstitial lung disease is well and truly open.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Informazioni ed Iscrizioni:
https://go.evvnt.com/921955-2?pid=4832
Ms. Aarti Diwan
Medicina General
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."
